相关实验视频
Updated: Sep 14, 2025

06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.2K
蛋白质翻译后修改:在缺血性心脏病中针对性治疗的新型分子开关和策略
Yuanyuan Chen1, Gaojie Xin2, Xiaoshan Cui1
1Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
概括
蛋白质后翻译修饰 (PTMs) 是理解缺血性心脏病 (IHD) 和开发新治疗方法的关键. 本综述涵盖了IHD中的PTM,其机制以及新的治疗策略.
科学领域:
- 生物化学和分子生物学
- 心血管研究研究心血管研究
- 蛋白质组学是指蛋白质组学.
背景情况:
- 蛋白质后翻译性修饰 (PTMs) 作为蛋白质功能和细胞信号的关键调节者.
- 缺血性心脏病 (IHD) 的发病因子越来越多地与失调的PTMs有关.
- 了解PTM为IHD提供了新的治疗点.
研究的目的:
- 在IHD的背景下提供PTM的全面审查.
- 阐明PTMs在IHD病理学中的分子机制和关键目标.
- 评估潜在的治疗策略,并为IHD管理提出精确干预方法.
主要方法:
- 在缺血性心脏病 (IHD) 中对PTM的文献综述.
- 对PTM参与IHD的分子机制的分析.
- 评估治疗目标和策略,包括激酶调制剂和基因编辑.
主要成果:
- 在IHD中确定了关键的PTM:酸化,乙化,无化,SUMOylation,糖化,乳化和糖化.
- 详细介绍了PTMs在心肌能量代谢,平衡,炎症,细胞死亡和纤维化中的作用.
- 突出了PTM调节剂和基因编辑的潜在治疗应用.
结论:
- PTM在缺血性心脏病 (IHD) 的发病过程中发挥着关键作用.
- 针对特定的PTM为IHD提供了有前途的治疗途径.
- 一个"修改原子学"指导的精确干预策略为IHD管理提供了一种新的方法.
相关概念视频
Atherosclerosis III: Management
36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Coronary Artery Disease V: Interprofessional Care
34
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
34
Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Covalently Linked Protein Regulators
7.2K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
7.2K

